Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANDATE HCT vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Treatment of hypertension,Management of hypertensive urgency (off-label)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.
250 mg orally twice daily
Labetalol: terminal elimination half-life is 6-8 hours (range 3-16 hours) consistent with twice-daily dosing. Hydrochlorothiazide: terminal half-life 9-10 hours (range 6-15 hours), prolonged in renal impairment.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Labetalol is extensively metabolized primarily via glucuronidation (direct conjugation) and minor CYP2D6-mediated oxidation to an inactive metabolite. Hydrochlorothiazide is not metabolized; it is excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Labetalol is primarily excreted in urine as unchanged drug (approximately 55-60%) and as glucuronide conjugates. About 12-27% is excreted in feces via biliary elimination. Hydrochlorothiazide is excreted unchanged in urine (≥95%) via renal tubular secretion. Total renal elimination of labetalol: ~55-60% unchanged; HCTZ: ~95% unchanged.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Labetalol: ~50% bound to albumin. Hydrochlorothiazide: ~40-68% bound to albumin and alpha-1-acid glycoprotein.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Labetalol: Vd 3-16 L/kg (mean 11 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: Vd 0.8-1.5 L/kg (mean 1 L/kg), limited distribution.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Labetalol: oral bioavailability is 25-40% due to extensive first-pass metabolism. Hydrochlorothiazide: oral bioavailability is 65-75% (fasted).
70-90% (oral); 100% (IV).
GFR 30-90 m L/min: No adjustment. GFR <30 m L/min: Contraindicated due to hydrochlorothiazide component.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: Use with caution; reduce labetalol dose. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism of labetalol.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended; safety and efficacy not established for labetalol/hydrochlorothiazide combination.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at lowest dose (100/25 mg daily); titrate slowly due to increased risk of hypotension and electrolyte imbalance.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Beta-blocker withdrawal: abrupt discontinuation may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease. Bronchospasm: avoid in patients with bronchial asthma or COPD. Heart failure: caution in patients with decompensated heart failure; may precipitate worsening. Peripheral vascular disease: may worsen symptoms. Hepatic impairment: labetalol is hepatically metabolized; use caution. Renal impairment: hydrochlorothiazide may be ineffective with Cr Cl <30 m L/min. Electrolyte disturbances: monitor potassium, sodium, magnesium; risk of hypokalemia, hyponatremia, hypomagnesemia. Hyperuricemia: can precipitate gout. Photosensitivity: with hydrochlorothiazide. Exacerbation of systemic lupus erythematosus: reported with thiazides. DM: beta-blockers may mask hypoglycemia. Surgery: withdrawal before elective surgery recommended.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Absolute: sinus bradycardia, heart block greater than first degree, cardiogenic shock, decompensated heart failure, bronchial asthma, hypersensitivity to labetalol, hydrochlorothiazide, or sulfonamide-derived drugs, anuria. Relative: diabetes mellitus, hyperthyroidism, pheochromocytoma (labetalol may paradoxically elevate blood pressure), severe renal impairment (Cr Cl <30 m L/min for thiazide efficacy).
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented soy products) due to potential hypertensive crises. Limit caffeine intake; may increase heart rate. Avoid excessive potassium-rich foods or supplements unless monitored due to hydrochlorothiazide's potassium-wasting effect. Take with food to reduce GI upset.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, hypoglycemia, and respiratory depression; intrauterine growth restriction reported with chronic use.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Labetalol is excreted into breast milk in low amounts (M/P ratio ~0.6-0.8); generally considered compatible with breastfeeding; monitor infant for bradycardia and hypotension.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No standard dose adjustment required; however, pregnancy may alter labetalol pharmacokinetics (increased clearance, decreased half-life) potentially necessitating dose titration based on clinical response.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Trandate HCT combines labetalol (alpha/beta blocker) and hydrochlorothiazide. Monitor heart rate, blood pressure, and electrolytes. Avoid in asthma, COPD, bradycardia, heart block, and anuria. Taper if discontinuing. May mask hypoglycemia in diabetics. Can cause orthostatic hypotension; dose at bedtime initially.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed, usually once daily, with or without food.,Do not stop suddenly; tapering is necessary to avoid rebound hypertension.,May cause dizziness or lightheadedness; rise slowly from sitting or lying.,Avoid alcohol; it can worsen dizziness and side effects.,Inform your doctor if you experience slow heartbeat, fainting, swelling of feet/ankles, or unusual weight gain.,May cause photosensitivity; use sunscreen and protective clothing.,Monitor blood pressure regularly at home.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANDATE HCT vs ALDOCLOR-250, answered by our medical review team.
TRANDATE HCT is a Antihypertensive Combination that works by TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANDATE HCT and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANDATE HCT is: Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANDATE HCT and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANDATE HCT is classified as Category C. First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, . ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.